Cargando…

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

BACKGROUND: The epidermal growth factor receptor (EGFR)/RAS/RAF/MEK/MAPK pathway is an important pathway in the carcinogenesis, invasion and metastasis of colorectal cancers (CRCs). We conducted a retrospective study to determine the prognostic values of EGFR expression and KRAS mutation in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Ching-Wen, Tsai, Hsiang-Lin, Chen, Yi-Ting, Huang, Chun-Ming, Ma, Cheng-Jen, Lu, Chien-Yu, Kuo, Chao-Hung, Wu, Deng-Chyang, Chai, Chee-Yin, Wang, Jaw-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878756/ https://www.ncbi.nlm.nih.gov/pubmed/24330663 http://dx.doi.org/10.1186/1471-2407-13-599

Ejemplares similares

Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver-only and lung-only metastases
por: Chuang, Shih-Chang, et al.
Publicado: (2020)

Two rare cases of synchronous and metachronous colonic metastases in patients with advanced gastric cancer
por: Su, Wei-Chih, et al.
Publicado: (2018)

Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer
por: Kim, Kyu-pyo, et al.
Publicado: (2017)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function
por: Huang, Ching-Wen, et al.
Publicado: (2017)

Prognostic Significance of C-Reactive Protein Polymorphism and KRAS/BRAF in Synchronous Liver Metastasis from Colorectal Cancer
por: Huang, Chi-Jung, et al.
Publicado: (2013)

Surgical resection of synchronous and metachronous lung and liver metastases of colorectal cancers
por: Jeong, Shinseok, et al.
Publicado: (2017)

Mesothelioma and Colorectal Cancer: Report of Four Cases with Synchronous and Metachronous Presentation
por: Serio, Gabriella, et al.
Publicado: (2022)

Incidence and Survival in Synchronous and Metachronous Liver Metastases From Colorectal Cancer
por: Reboux, Noémi, et al.
Publicado: (2022)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma
por: Pape, Marieke, et al.
Publicado: (2022)

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports
por: Li, Ching-Chun, et al.
Publicado: (2018)

Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups
por: Gok Durnali, Ayse, et al.
Publicado: (2016)

Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
por: Huang, Ching-Wen, et al.
Publicado: (2021)

Synchronous Metastatic Clear Cell Renal Cell Carcinoma to the Gallbladder With Metachronous Contralateral Recurrence
por: Pierce, Daniel P, et al.
Publicado: (2021)

Survival after resection of brain metastasis: impact of synchronous versus metachronous metastatic disease
por: Potthoff, Anna-Laura, et al.
Publicado: (2023)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

A rare case of metachronous neuroendocrine tumor after a colorectal adenocarcinoma: qualitative critical review of synchronous and metachronous gastrointestinal NET
por: Lancellotti, Francesco, et al.
Publicado: (2020)

The different clonal origins of metachronous and synchronous metastases
por: Gofrit, Ofer N., et al.
Publicado: (2023)

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases
por: Mekenkamp, L J M, et al.
Publicado: (2010)

Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases
por: Zheng, Peng, et al.
Publicado: (2018)

Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer
por: Bartolini, Ilenia, et al.
Publicado: (2018)

Clinicopathologic and Prognostic Association of GRP94 Expression in Colorectal Cancer with Synchronous and Metachronous Metastases
por: Yun, Sumi, et al.
Publicado: (2021)

Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population‐based study
por: Väyrynen, V., et al.
Publicado: (2020)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

Synchronous/Metachronous Multiple Primary Malignancies: Review of Associated Risk Factors
por: Pan, Szu-Ying, et al.
Publicado: (2022)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

Synchronous and metachronous liver metastases in patients with colorectal cancer—towards a clinically relevant definition
por: Engstrand, Jennie, et al.
Publicado: (2019)

Retrospective study of prognosis of patients with multiple colorectal carcinomas: synchronous versus metachronous makes the difference
por: Barz, Christoph, et al.
Publicado: (2021)

Differences in genome, transcriptome, miRNAome, and methylome in synchronous and metachronous liver metastasis of colorectal cancer
por: Horak, Josef, et al.
Publicado: (2023)

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab
por: Chang, Tsung-Kun, et al.
Publicado: (2021)

Metastatic or metachronous adamantinoma: An Enigma
por: Ramaswamy, AS, et al.
Publicado: (2012)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
por: Quéré, Gilles, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tafu5dk9d289tdqh9avcj9uk8e